PRAME
A protein normally confined to testis that most melanomas and many other cancers switch on; T-cell receptor drugs can recognise fragments of it.
Preferentially Expressed Antigen in Melanoma is a cancer-testis antigen expressed in ~90% of cutaneous melanomas and in substantial fractions of ovarian, lung, endometrial, and uveal cancers. Intracellular, so reachable only via peptide–HLA recognition: brenetafusp (ImmTAC), IMA203 (Immatics TCR-T, phase 3 in melanoma), and other TCR programmes. PRAME immunohistochemistry is also a diagnostic aid for distinguishing melanoma from naevi.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · A protein normally confined to testis that most melanomas and many other cancers switch on; T-cell receptor drugs can recognise fragments of it.
- 1 · What it is
A protein normally confined to testis that most melanomas and many other cancers switch on; T-cell receptor drugs can recognise fragments of it.
- 2 · What goes wrong in cancer
Represses retinoic acid receptor signalling; drives proliferation and blocks differentiation; presented on HLA class I as peptides such as PRAME 425-433 on A*02:01.
- 3 · How drugs use it
1 product aims at PRAME: bispecific antibodies. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Biology
Represses retinoic acid receptor signalling; drives proliferation and blocks differentiation; presented on HLA class I as peptides such as PRAME 425-433 on A*02:01.
- Cutaneous melanoma (~90%)
- Uveal melanoma (subset, associated with metastasis)
- Ovarian, endometrial, NSCLC, breast (subsets)
- Synovial sarcoma
How common it is, by cancer
Latest papers
topQuery for this target: (TITLE:"PRAME" OR ABSTRACT:"PRAME") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PRAME, not a curated reading list.
Pages like this
not linked directly; found by shared links- Targetgp100 (PMEL)
Shares Uveal melanoma, Antigen presentation & immune editing, TCR-T cell therapy, T-cell engagers (bispecific) and the tag tcr-target.
- TargetMAGE-A4
Shares Antigen presentation & immune editing, TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST), Melanoma and the tag tcr-target.
- ProductTebentafusp
Shares TCR therapeutics for non-HLA-A*02 patients, Immunocore, Brenetafusp, HLA-A*02:01 restriction.
- IdeaAntibodies that see mutant KRAS and p53 fragments displayed on the cell surface
Shares Immatics, Immunocore, TCR-T cell therapy, T-cell engagers (bispecific).
- InstitutionOxford Cancer – Oxford University Hospitals and University of Oxford
Shares Immunocore, T-cell engagers (bispecific), Ovarian cancer, Melanoma.
- TrialIMCgp100-202
Shares Immunocore, T-cell engagers (bispecific), Melanoma.
- InstitutionComprehensive Cancer Center Tübingen-Stuttgart
Shares Immatics, TCR-T cell therapy, Melanoma.
- InstitutionQIMR Berghofer Medical Research Institute
Shares TCR-T cell therapy, Ovarian cancer, Melanoma.